特一药业(002728) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥295,133,348.45, representing a 79.29% increase compared to ¥164,611,744.46 in the same period last year[5] - Net profit attributable to shareholders was ¥31,567,273.65, a significant increase of 244.82% from ¥9,154,620.96 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥31,706,892.60, reflecting a 255.28% increase from ¥8,924,581.10 in the previous year[5] - Basic earnings per share increased to ¥0.06, a 200.00% rise from ¥0.03 in the previous year[5] - Operating profit for the current period was ¥39,868,269.15, compared to ¥11,312,896.62 in the previous period, reflecting an increase of approximately 252.5%[17] - The net profit for the current period is 31,567,273.65, compared to 9,154,620.96 in the previous period, representing a significant increase[18] Cash Flow - Operating cash flow net amount improved to ¥89,383,755.80, a 327.00% increase from -¥39,376,492.11 in the same period last year[5] - Cash inflow from operating activities totaled 335,732,874.13, compared to 167,275,775.68 in the previous period, indicating a growth of 100.5%[20] - The net cash flow from operating activities is 89,383,755.80, a turnaround from a negative cash flow of -39,376,492.11 in the previous period[20] - Cash outflow from investing activities was 159,330,790.44, compared to 66,834,461.53 in the previous period, reflecting an increase of 138.2%[21] - The net cash flow from investing activities is -68,944,379.48, worsening from -46,812,491.92 in the previous period[21] - Cash inflow from financing activities was 274,580,687.52, down from 292,915,169.80 in the previous period[22] - The net cash flow from financing activities is -143,692,283.28, compared to -78,472,431.97 in the previous period, indicating a decline[22] - The ending cash and cash equivalents balance is 179,708,816.53, down from 382,154,235.62 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,221,913,600.05, a decrease of 7.45% from ¥2,400,875,824.19 at the end of the previous year[5] - Current assets decreased from ¥950,947,063.46 to ¥777,616,074.33, a reduction of approximately 18.2%[16] - Cash and cash equivalents dropped from ¥457,414,315.11 to ¥230,161,408.15, a decrease of about 49.7%[16] - Short-term borrowings decreased significantly from ¥516,093,372.63 to ¥260,000,000.00, a reduction of approximately 49.6%[16] - The total liabilities decreased from ¥635,942,585.62 to ¥423,433,632.10, a decline of about 33.4%[16] - The company's retained earnings increased from ¥353,494,039.54 to ¥385,061,313.19, an increase of approximately 8.9%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 63,146[10] - The largest shareholder, Xu Danqing, holds 27.31% of the shares, totaling 139,973,400 shares[10] - The top ten shareholders include both individual and institutional investors, with significant holdings by Xu family members[11] - There are no preferred shareholders reported in the current period[12] Marketing and Investment - The company reported a significant increase in sales expenses, which rose by 238.02% to ¥85,855,783.63 due to increased investment in new media advertising[9] - Brand building investment amounted to 106 million RMB during the reporting period[12] - The company is undergoing marketing organizational changes and brand marketing construction since 2024, with initial positive results[12] - The company emphasizes risk prevention and financial strategy optimization amid ongoing marketing reforms[12] - The company maintains a focus on long-term development while adapting to market changes[12] - The company warns investors to be aware of investment risks due to ongoing marketing reforms[12] Research and Development - Research and development expenses were ¥9,512,915.33, down from ¥11,100,583.43, indicating a decrease of about 13.5%[17] Other Information - The company has not undergone an audit for the first quarter report[23]